In a nutshell This article reviewed the effectiveness and safety of CAR T-cell therapy in patients with non-Hodgkin’s lymphoma. Some background The standard treatment for non-Hodgkin’s lymphoma (NHL) is chemotherapy plus immunotherapy. Patients with high-risk disease tend to become refractory (do not respond to treatment). For these...
Read More
In a nutshell This study investigated respiratory side effects in patients with non-Hodgkin’s lymphoma (NHL) who received chemotherapy containing rituximab (Rituxan). This study concluded that these side effects are common and associated with increased mortality in these patients. Some background Non-Hodgkin’s lymphoma patients treated...
Read MoreIn a nutshell This study investigated the safety and effectiveness of rituximab (Rituxan) plus bortezomib (Velcade) for patients with mantle cell lymphoma after stem cell transplant. This study concluded that this combination is a safe and effective regimen in these patients. Some background The standard treatment for younger patients with mantle cell...
Read More
In a nutshell This study investigated the effects of fixed-dose (FD) and weight-based (WB) dose plerixafor (Mozobil) on hematopoietic stem cell (HSC) movement in patients with Non-Hodgkin’s lymphoma (NHL) weighing less than 11 stone. The main finding was that there was no significant difference in HSC movement with WB or FD plerixafor. Some...
Read MoreIn a nutshell This article reviewed the treatment options for patients with very high-risk diffuse large B-cell lymphoma (DLBCL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. DLBCL patients with certain risk factors may develop relapsed disease in the brain. The...
Read MoreIn a nutshell This article reviewed the treatment options for patients with very high-risk diffuse large B-cell lymphoma (DLBCL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. DLBCL patients with certain risk factors may develop relapsed disease in the brain. The...
Read More
In a nutshell This study reviewed current and new targeted therapies for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. Some background Ibrutinib (Imbruvica) remains the current standard of care for patients with mantle cell lymphoma (MCL) who relapse or develop refractory disease after initial...
Read More
In a nutshell This study reviewed current and new targeted therapies for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. Some background Ibrutinib (Imbruvica) remains the current standard of care for patients with mantle cell lymphoma (MCL) who relapse or develop refractory disease after initial...
Read More
In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...
Read More
In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...
Read MoreIn a nutshell This study investigated the effects of different chemotherapies on the survival outcomes of elderly patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CHOP treatment is associated with very good survival in elderly patients with DLBCL. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...
Read MoreIn a nutshell This study investigated the effects of different chemotherapies on the survival outcomes of elderly patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CHOP treatment is associated with very good survival in elderly patients with DLBCL. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...
Read More
